Shots:
- The approval is based on data from the SYNAPSE study evaluating mepolizumab vs PBO in ~400 patients with CRSwNP who had a history of prior surgery & need further surgery due to severe symptoms & increased size of polyps
- The results showed a 57% reduction in the size of nasal polyps & nasal obstruction in patients who had surgery whereas the proportion of patients requiring systemic corticosteroid use through 52 wks. of the treatment period was lower who received the therapy
- Mepolizumab is the 1st anti-IL-5 biologic to be approved for CRSwNP & marks the 4th indication for eosinophil-driven diseases in the US
Click here to read full press release/ article | Ref: Businesswire | Image: Fierce Pharma
The post GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps first appeared on PharmaShots.
